SERUM CYSTATIN C IN MURINE TUMORS TREATED BY COMBINATIONS OF CYCLOPHOSPHAMIDE WITH UKRAIN OR GLUCANS

USOVA Т.А.¹, POTERYAEVA O.N.², FALAMEYEVA O.V.¹, ZHANAEVA S.Y.¹, LEVINA O.A.¹, YARYGINA E.S.¹, KOROLENKO T.A.¹, NOWICKY J.³

1)  Institute of Physiology, Siberian Branch of Russian Academy of Medical Sciences, Novosibirsk, Russia.
2)  Institute of Biochemistry, Siberian Branch of Russian Academy of Medical Sciences, Novosibirsk, Russia.
3)  Ukrainian Anti-Cancer Institute, Vienna, Austria.

Address for correspondence: T.A. Usova, Laboratory of Cellular Biochemistry, Institute of Physiology, Russian Academy of Medical Sciences, ul. Timakova 4, 630117 Novosibirsk, Russia.

Summary: The antitumor drug Ukrain exerted malignotoxic effect in vivo and was effective in the treatment of some malignancies in experimental animals as a result of immunostimulation. Serum concentration of cystatin C, an endogenous cysteine protease inhibitor, was measured in a murine tumor model of Lewis lung adeno­carcinoma during cyclophosphamide treatment combined with Ukrain or glucans. It was shown that in murine Lewis lung adenocarcinoma serum cystatin C concentration decreased approximately 2-fold, while Ukrain treat­ment combined with cyclophosphamide restored serum cystatin C levels to the normal value. Similar results were obtained using a combination of cyclophosphamide with some glucans, biological response modifiers.